Radio and PodcastRadio and PodcastLive Radio & Podcasts
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib artwork
Science & Medicine

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patients with cancer by American Medical Association

Nov 21, 202418:46Science & Medicine

Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Cont...

About This Episode

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib is an episode from JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patients...

Podcast

This episode belongs to JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patients with cancer.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Nov 21, 2024, 18:46 long, audio available.

Related Episodes

Continue listening to more episodes from JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patients with cancer.

Questions About This Episode

What is Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib about?

Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

Where can I listen to Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib?

You can listen to Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib online on Radio and Podcast. Open the player on this page to stream the available audio.

Which podcast is Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib from?

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib is an episode from JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patients with cancer by American Medical Association.

How long is this episode?

This episode is 18:46 long.

When was this episode published?

This episode was published on Nov 21, 2024.

Can I save Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib for later?

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Are there related episodes from JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patients with cancer?

Yes. This page shows related episodes from JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patients with cancer when more episodes are available from the podcast feed.

Quick Answers About This Episode

Where can I listen to Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib?

You can listen to Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib on this page when the episode audio is available from the podcast feed.

Which podcast is this episode from?

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib is from JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patients with cancer by American Medical Association.

What are the episode details?

Published Nov 21, 2024 and 18:46 long